VivoSeq
Other

Hysterectomy

100

Pipeline Programs

28

Active Trials

44

Companies Involved

Hysterectomy is a moderately active landscape with 100 programs across 44 companies. The most active players are Milestone Pharmaceuticals Inc., Amring, Cara Therapeutics, Inc.. 54 therapies are approved with 13 more in late-stage development.

Pipeline Metrics

Competitive Density

71/100

Pipeline Velocity

30/100

Mech. Concentration

18/100

Completion Rate

91/100

Attrition Rate

6/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Programs by Phase

Trial Status

135

clinical trials

Completed78 · 58%
Unknown status21 · 16%
Recruiting18 · 13%
Not yet recruiting7 · 5%
Terminated4 · 3%
Withdrawn4 · 3%
Other3 · 2%

Trial Activity

135 trials

Bupivacaine for Postoperative Pain After Laparoscopic Hysterectomy
Recruiting··N/A·NCT07435909·120 enrolled
Page 1 of 9

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)